Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main purpose of this study is to evaluate the safety, efficacy and tolerability of ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function.
The study consists of 2 parts: part A comprises the main study period, and part B comprises the long-term observational follow-up period. During part A, after the screening period, eligible participants will be randomized to receive either ARGX-117 or placebo, entering the treatment and evaluation period (duration of up to 52 weeks). After the treatment period, participants will enter a follow-up period of up to 12 weeks.
The total study duration varies from approximately 64 weeks up to 5 years post-transplant depending on whether a participant enrols in part B of the study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
The full list of criteria can be found in the protocol.
Primary purpose
Allocation
Interventional model
Masking
102 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Sabine Coppieters, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal